Trial Profile

A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions
Acronyms ZUMA-8
Sponsors Kite Pharma

Most Recent Events

24 Nov 2023 This trial has been completed in Germany (Date of the global end of the trial: 17-Nov-2022), according to the European Clinical Trials Database record.
31 Oct 2023 Number of treatment arms increased from 4 to 5 by the addition of Experimental: Second Stage Cohort 4B arm.
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com